The ALX2004 molecule, created entirely in ALX Oncology labs, comprises an antibody backbone engineered to optimize anti-EGFR activity, a linker with enhanced stability and a proprietary topoisomerase ...

our Ly6E-targeting antibody-drug conjugate incorporating our proprietary topoisomerase 1 inhibitor payload, ZD06519. These preclinical findings demonstrate how our therapeutic approaches have the ...

Utilization of a superior Ly6E binding and internalizing antibody with a proprietary topoisomerase 1 inhibitor payload, ZD06519, lends ZW327 a highly differentiated profile, with pronounced in ...

comprises an antibody backbone engineered to optimize anti-EGFR activity, a linker with enhanced stability and a proprietary topoisomerase I payload that can generate an enhanced bystander effect.

Utilization of a superior Ly6E binding and internalizing antibody with a proprietary topoisomerase 1 inhibitor payload, ZD06519, lends ZW327 a highly differentiated profile, with pronounced in ...

“Among these, we are excited to share updates on ZW209, our DLL3-targeting trispecific T cell engager incorporating co-stimulation, which is on track for IND submission in 1H-2026, and ZW327, our Ly6E ...

"Among these, we are excited to share updates on ZW209, our DLL3-targeting trispecific T cell engager incorporating co-stimulation, which is on track for IND submission in 1H-2026, and ZW327, our Ly6E ...